AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment
Information source: Mclean Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depressive Disorder, Major
Intervention: Testosterone gel (Drug); Placebo (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Mclean Hospital Official(s) and/or principal investigator(s):
Harrison G Pope, M.D., Principal Investigator, Affiliation: Mclean Hospital
Stuart N Seidman, M.D., Principal Investigator, Affiliation: Columbia University
Summary
We hypothesize that AndroGel may offer some relief to subjects with low or borderline
testosterone levels who suffer from depression and have failed to respond to a trial of a
standard antidepressant.
During this nine week, outpatient, double-blind study, male subjects between the ages of 30
and 65 years with treatment-refractory depression and low or borderline low testosterone
levels will be treated with either AndroGel or placebo. Following this nine week,
double-blind phase, eligible subjects will have the option to continue into a six month,
open-label phase during which time all subjects will receive the AndroGel patch.
Clinical Details
Official title: A Parallel-Group, Placebo-Controlled Trial of AndroGel in Men With Major Depressive Disorder Who Display an Incomplete Response to Standard Antidepressant Treatment
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Hamilton Depression Rating Scale
Secondary outcome: Montgomery Asberg Depression Rating Scale
Detailed description:
We will recruit 100 men between the ages of 30 and 65 years who have treatment-refractory
depression and low or borderline low testosterone levels for participation in this study.
For a period of nine weeks subjects will receive double-blind treatment with either AndroGel
(testosterone gel) or placebo. During this double-blind treatment phase subjects will come to
McLean Hospital for a total of seven visits. Both clinical assessments (including ratings of
your levels of depression and anxiety, quality of life, and visuospatial memory)and
laboratory tests will be performed at these visits. Following the nine week, double-blind
phase, eligible subjects may enter into a six month, open-label treatment phase in which all
subject receive AndroGel. If you participate in the open-label phase, you will be asked to
return to the site for 8 visits during the six month period.
Eligibility
Minimum age: 30 Years.
Maximum age: 65 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Male
- 30-65 years old
- Taking at least one serotonergic antidepressant at adequate dose for at least six
weeks but still meeting DSM-IV criteria for major depressive disorder within the past
year
- HAM-D score >12
Exclusion Criteria:
- Current suicidal ideation
- Substance abuse or dependence within the past year
- Current or past psychotic symptoms
- A history of bipolar disorder
- A prostate-specific antigen (PSA) level greater than 4. 0 ng/ml
- Other clinically significant medical condition
- A history of failing to show any clinically significant response to two or more
adequate trials of different antidepressants.
Locations and Contacts
The Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel
McLean Hospital, Belmont, Massachusetts 02478, United States
Additional Information
Starting date: April 2006
Ending date: June 2008
Last updated: March 26, 2008
|
